Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies

Inclusion Criteria: 1. Patients with indications for hematopoietic stem cell transplantation; 2. Age ≤75 years old; 3. Confirmed B-cell tumor and tumor cells expressing CD19； 4. Expected survival time \>12 weeks; 5. ECOG score is 0-2; 6. Adequate liver , kidney and cardiopulmonary function; 7. Willingness to complete the informed consent process and to comply with study procedures and visit schedule. Exclusion Criteria: 1. Had received NK cell therapy or other genetically modified cell therapy within 1 year before screening; 2. At least 14 days or at least 5 half-lives of antitumor therapy had elapsed before screening; 3. Patients who had undergone hematopoietic stem cell transplantation (ASCT), allogeneic hematopoietic stem cell transplantation (HSCT), or solid organ transplantation within 12 weeks before screening; Grade 2 or higher GVHD requiring immunosuppressive therapy occurred within 2 weeks before screening; 4. Patients with atrial or ventricular lymphoma or need urgent treatment due to tumor mass such as intestinal obstruction or vascular compression; 5. Have received live attenuated vaccine within 6 weeks before rinsing; 6. Had a cerebrovascular accident or seizure within 6 months before screening; 7. History of deep venous thrombosis or pulmonary embolism within 6 months before screening; 8. A history of myocardial infarction, bypass or stent bypass, unstable angina, or other clinically significant heart disease within 12 months prior to screening; 9. Previous history of Alzheimer's disease; 10. Autoimmune diseases leading to end-organ damage or requiring systemic immunosuppression (e.g. Crohns, rheumatoid arthritis, systemic lupus erythematosus) within 2 years prior to screening; 11. There are uncontrollable infections; 12. Women who are pregnant or breastfeeding; Or women of childbearing age who have positive pregnancy tests during the screening period; Male or female patients who did not wish to use contraception from the time of signing the informed consent to 1 year after receiving the NK cell infusion; 13. Conditions that other researchers deemed inappropriate for participating in the study.